An emerging market sector that has recently been subject to increased investor attention has been psychedelics. Generally speaking, this refers to businesses focused on the potential medical, therapeutic and recreational uses of psilocybin, which is the naturally occurring hallucinogen that is found in certain mushrooms, and ketamine, a synthetic compound primarily used as an anesthetic. Both psilocybin and ketamine are designated as controlled substances under Canada’s Controlled Substances and Drugs…
Whether for public companies or private corporations, the rights and remedies of minority and dissenting shareholders are ever expanding.
Our litigators know precisely how best to advance those shareholder interests against the corporations in which they invest, the boards that manage the corporations, other shareholders, and the brokers who had them acquire shares. And they know how to do so before the courts or in private arbitration to ensure that shareholders are treated fairly and justly.
But we also understand very well the limits of such shareholder rights. Corporations and boards of directors have, as a matter of course, frequently turned to us to enforce those limits.